Trial · NCT04447989
Results by group85
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 85
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety Based Upon Number of Participants With Hypotension | Cohort 1, Sildenafil | 1 | Participants | ||
| Safety Based Upon Number of Participants With Hypotension | Cohort 2, Sildenafil | 0 | Participants | ||
| Safety Based Upon Number of Participants With Hypotension | Cohort 3, Sildenafil | 0 | Participants | ||
| Safety Based Upon Number of Participants With Hypotension | Placebo | 0 | Participants | ||
| Central Volume of Distribution (Vc) Population Pharmacokinetics (popPK) | Pharmacokinetics (PK) Cohort | 3.86 | 95% Confidence Interval 1.28 to 11.07 | L | |
| Peripheral Volume of Distribution (Vp) Population Pharmacokinetics (popPK) | Pharmacokinetics (PK) Cohort | 4.49 | 95% Confidence Interval 2.87 to 6.66 | L | |
| Clearance Population Pharmacokinetics (popPK) | Pharmacokinetics (PK) Cohort | 2.69 | 95% Confidence Interval 1.00 to 7.94 | L/h | |
| Half-life Population Pharmacokinetics (popPK) | Pharmacokinetics (PK) Cohort | 8.79 | Inter-Quartile Range 8.00 to 9.42 | hours | |
| Peak Plasma Concentration Population Pharmacokinetics (popPK) | Pharmacokinetics (PK) Cohort | 130.5 | Inter-Quartile Range 70.9 to 256.0 | ng/mL | |
| Number of Participants at Each Global Rank | Cohort 1, Sildenafil | Mortality | 0 | Participants | |
| Number of Participants at Each Global Rank | Cohort 2, Sildenafil | Mortality | 2 | Participants | |
| Number of Participants at Each Global Rank | Cohort 3, Sildenafil | Mortality | 1 | Participants | |
| Number of Participants at Each Global Rank | Placebo | Mortality | 0 | Participants | |
| Number of Participants at Each Global Rank | Cohort 1, Sildenafil | Extracorporeal life support | 0 | Participants | |
| Number of Participants at Each Global Rank | Cohort 2, Sildenafil | Extracorporeal life support | 0 | Participants | |
| Number of Participants at Each Global Rank | Cohort 3, Sildenafil | Extracorporeal life support | 0 | Participants | |
| Number of Participants at Each Global Rank | Placebo | Extracorporeal life support | 0 | Participants | |
| Number of Participants at Each Global Rank | Cohort 1, Sildenafil | Tracheostomy | 8 | Participants | |
| Number of Participants at Each Global Rank | Cohort 2, Sildenafil | Tracheostomy | 3 | Participants | |
| Number of Participants at Each Global Rank | Cohort 3, Sildenafil | Tracheostomy | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04447989/results